Skip to content

Released Apr 2, 2018, after the close

10-K filed Apr 2, 2018, 92 days after period end · 0001564590-18-007402

Q4 2017 · 10-K
Revenue$993.00Kno prior Q4 2016 on file+66.3% vs Q3 2017
Net Income-$13.86MN/M vs Q4 2016N/M vs Q3 2017
EPS Diluted-$1.59N/M vs Q4 2016N/M vs Q3 2017
Operating Incomederived-$14,000,000—
Operating Cash Flowderived-$12,740,000N/M
Margins · derived
Operating margin-1409.9%
Net margin-1396.0%

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2017Q4 2016
Revenue$993.00K—
Net Income-$13.86M-$7.21M
EPS Diluted-$1.59-$25.68

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR